Product Name :
Giredestrant
Description:
Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
CAS:
1953133-47-5
Molecular Weight:
522.55
Formula:
C27H31F5N4O
Chemical Name:
3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol
Smiles :
C[C@@H]1CC2=C(NC3=CC=CC=C23)[C@@H](C2C(F)=CC(=CC=2F)NC2CN(CCCF)C2)N1CC(F)(F)CO
InChiKey:
GQCXHIKRWBIQMD-AKJBCIBTSA-N
InChi :
InChI=1S/C27H31F5N4O/c1-16-9-20-19-5-2-3-6-23(19)34-25(20)26(36(16)14-27(31,32)15-37)24-21(29)10-17(11-22(24)30)33-18-12-35(13-18)8-4-7-28/h2-3,5-6,10-11,16,18,26,33-34,37H,4,7-9,12-15H2,1H3/t16-,26-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.|Product information|CAS Number: 1953133-47-5|Molecular Weight: 522.55|Formula: C27H31F5N4O|Chemical Name: 3-[(1R,3R)-1-(2,6-difluoro-4-{[1-(3-fluoropropyl)azetidin-3-yl]amino}phenyl)-3-methyl-1H,2H,3H,4H,9H-pyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol|Smiles: C[C@@H]1CC2=C(NC3=CC=CC=C23)[C@@H](C2C(F)=CC(=CC=2F)NC2CN(CCCF)C2)N1CC(F)(F)CO|InChiKey: GQCXHIKRWBIQMD-AKJBCIBTSA-N|InChi: InChI=1S/C27H31F5N4O/c1-16-9-20-19-5-2-3-6-23(19)34-25(20)26(36(16)14-27(31,32)15-37)24-21(29)10-17(11-22(24)30)33-18-12-35(13-18)8-4-7-28/h2-3,5-6,10-11,16,18,26,33-34,37H,4,7-9,12-15H2,1H3/t16-,26-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 50 mg/mL (95.{{Datopotamab} MedChemExpress|{Datopotamab} Immunology/Inflammation|{Datopotamab} Protocol|{Datopotamab} In Vitro|{Datopotamab} manufacturer|{Datopotamab} Autophagy} 68 mM; Need ultrasonic).{{Mirtazapine} site|{Mirtazapine} Immunology/Inflammation|{Mirtazapine} Protocol|{Mirtazapine} Purity|{Mirtazapine} supplier|{Mirtazapine} Autophagy} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:24631563 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Giredestrant (GDC-9545) is a novel ER antagonist that combines desirable mechanistic and pre-clinical DMPK attributes. The highly potent in vivo efficacy of Giredestrant likely arises due to the particular combination of high binding potency, full suppression of ER signaling, and an improved DMPK profile.|Products are for research use only. Not for human use.|